Clinical Trial

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT07493993
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions ESCC
Enrollment 26 participants
Start Date 2026-06-01
Primary Completion 2028-05-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27